BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 37413906)

  • 21. Identification of a novel therapeutic candidate, NRK, in primary cancer-associated fibroblasts of lung adenocarcinoma microenvironment.
    Wei T; Song J; Liang K; Li L; Mo X; Huang Z; Chen G; Mao N; Yang J
    J Cancer Res Clin Oncol; 2021 Apr; 147(4):1049-1064. PubMed ID: 33387038
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting MEK in a Translational Model of Histiocytic Sarcoma.
    Takada M; Hix JML; Corner S; Schall PZ; Kiupel M; Yuzbasiyan-Gurkan V
    Mol Cancer Ther; 2018 Nov; 17(11):2439-2450. PubMed ID: 30135215
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of MEK suppresses hepatocellular carcinoma growth through independent MYC and BIM regulation.
    Zhou X; Zhu A; Gu X; Xie G
    Cell Oncol (Dordr); 2019 Jun; 42(3):369-380. PubMed ID: 30788663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single-cell transcriptome analysis demonstrates inter-patient and intra-tumor heterogeneity in primary and metastatic lung adenocarcinoma.
    Liu Y; Ye G; Huang L; Zhang C; Sheng Y; Wu B; Han L; Wu C; Dong B; Qi Y
    Aging (Albany NY); 2020 Nov; 12(21):21559-21581. PubMed ID: 33170151
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Establishment of an experimental model of normal dog bladder organoid using a three-dimensional culture method.
    Elbadawy M; Fujisaka K; Yamamoto H; Tsunedomi R; Nagano H; Ayame H; Ishihara Y; Mori T; Azakami D; Uchide T; Fukushima R; Abugomaa A; Kaneda M; Yamawaki H; Shinohara Y; Omatsu T; Mizutani T; Usui T; Sasaki K
    Biomed Pharmacother; 2022 Jul; 151():113105. PubMed ID: 35605292
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Standardization and Maintenance of 3D Canine Hepatic and Intestinal Organoid Cultures for Use in Biomedical Research.
    Gabriel V; Zdyrski C; Sahoo DK; Dao K; Bourgois-Mochel A; Kopper J; Zeng XL; Estes MK; Mochel JP; Allenspach K
    J Vis Exp; 2022 Jan; (179):. PubMed ID: 35156656
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MCL1 inhibition enhances the therapeutic effect of MEK inhibitors in KRAS-mutant lung adenocarcinoma cells.
    Tada M; Sumi T; Tanaka Y; Hirai S; Yamaguchi M; Miyajima M; Niki T; Takahashi H; Watanabe A; Sakuma Y
    Lung Cancer; 2019 Jul; 133():88-95. PubMed ID: 31200834
    [TBL] [Abstract][Full Text] [Related]  

  • 28. USP53 promotes apoptosis and inhibits glycolysis in lung adenocarcinoma through FKBP51-AKT1 signaling.
    Zhao X; Wu X; Wang H; Yu H; Wang J
    Mol Carcinog; 2020 Aug; 59(8):1000-1011. PubMed ID: 32511815
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Establishment of 2.5D organoid culture model using 3D bladder cancer organoid culture.
    Abugomaa A; Elbadawy M; Yamanaka M; Goto Y; Hayashi K; Mori T; Uchide T; Azakami D; Fukushima R; Yoshida T; Shibutani M; Yamashita R; Kobayashi M; Yamawaki H; Shinohara Y; Kaneda M; Usui T; Sasaki K
    Sci Rep; 2020 Jun; 10(1):9393. PubMed ID: 32523078
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of primary liver organoid culture from different stages of non-alcoholic steatohepatitis (NASH) mouse model.
    Elbadawy M; Yamanaka M; Goto Y; Hayashi K; Tsunedomi R; Hazama S; Nagano H; Yoshida T; Shibutani M; Ichikawa R; Nakahara J; Omatsu T; Mizutani T; Katayama Y; Shinohara Y; Abugomaa A; Kaneda M; Yamawaki H; Usui T; Sasaki K
    Biomaterials; 2020 Apr; 237():119823. PubMed ID: 32044522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Suppression of tumor immune microenvironment via microRNA-1 after epidermal growth factor receptor-tyrosine kinase inhibitor resistance acquirement in lung adenocarcinoma.
    Kawana S; Saito R; Miki Y; Kimura Y; Abe J; Sato I; Endo M; Sugawara S; Sasano H
    Cancer Med; 2021 Jan; 10(2):718-727. PubMed ID: 33305905
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Matrine is a novel inhibitor of the TMEM16A chloride channel with antilung adenocarcinoma effects.
    Guo S; Chen Y; Pang C; Wang X; Shi S; Zhang H; An H; Zhan Y
    J Cell Physiol; 2019 Jun; 234(6):8698-8708. PubMed ID: 30370542
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
    Lee JW; Zhang Y; Eoh KJ; Sharma R; Sanmamed MF; Wu J; Choi J; Park HS; Iwasaki A; Kaftan E; Chen L; Papadimitrakopoulou V; Herbst RS; Koo JS
    J Thorac Oncol; 2019 Jun; 14(6):1046-1060. PubMed ID: 30771521
    [TBL] [Abstract][Full Text] [Related]  

  • 34. GPR37 promotes cancer growth by binding to CDK6 and represents a new theranostic target in lung adenocarcinoma.
    Xie X; Cai X; Zhou F; Li Y; Liu Q; Cai L; Zhu W; Wei J; Jin C; Liu Z; Jiang C; Zhao H; Yang L; Zhao C; Huang X
    Pharmacol Res; 2022 Sep; 183():106389. PubMed ID: 35934193
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient-Derived Organoids of Cholangiocarcinoma.
    Maier CF; Zhu L; Nanduri LK; Kühn D; Kochall S; Thepkaysone ML; William D; Grützmann K; Klink B; Betge J; Weitz J; Rahbari NN; Reißfelder C; Schölch S
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445380
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progress and perspective of organoid technology in cancer-related translational medicine.
    Lin Y; Jiang L; He Q; Yuan M; Cao J
    Biomed Pharmacother; 2022 May; 149():112869. PubMed ID: 35358798
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting YAP-p62 signaling axis suppresses the EGFR-TKI-resistant lung adenocarcinoma.
    Park HS; Lee DH; Kang DH; Yeo MK; Bae G; Lee D; Yoo G; Kim JO; Moon E; Huh YH; Lee SH; Jo EK; Cho SY; Lee JE; Chung C
    Cancer Med; 2021 Feb; 10(4):1405-1417. PubMed ID: 33486901
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RAS signaling in ALK fusion lung cancer.
    Hrustanovic G; Bivona TG
    Small GTPases; 2016; 7(1):32-3. PubMed ID: 26901483
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MEK inhibition suppresses metastatic progression of KRAS-mutated gastric cancer.
    Yamasaki J; Hirata Y; Otsuki Y; Suina K; Saito Y; Masuda K; Okazaki S; Ishimoto T; Saya H; Nagano O
    Cancer Sci; 2022 Mar; 113(3):916-925. PubMed ID: 34931404
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The ERBB network facilitates KRAS-driven lung tumorigenesis.
    Kruspig B; Monteverde T; Neidler S; Hock A; Kerr E; Nixon C; Clark W; Hedley A; Laing S; Coffelt SB; Le Quesne J; Dick C; Vousden KH; Martins CP; Murphy DJ
    Sci Transl Med; 2018 Jun; 10(446):. PubMed ID: 29925636
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.